Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Huber H, Tausch E, Schneider C, Edenhofer S, von Tresckow J, Robrecht S, Giza A, Zhang C, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Al-Sawaf O, Kreuzer KA, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Huber H, et al. Blood. 2023 Sep 14;142(11):961-972. doi: 10.1182/blood.2023020013. Blood. 2023. PMID: 37363867 Free article.
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk.
Winkler D, Schneider C, Zucknick M, Bögelein D, Schulze K, Zenz T, Mohr J, Philippen A, Huber H, Bühler A, Habermann A, Benner A, Döhner H, Stilgenbauer S, Mertens D. Winkler D, et al. Among authors: huber h. Haematologica. 2010 Nov;95(11):1880-8. doi: 10.3324/haematol.2010.025734. Epub 2010 Aug 16. Haematologica. 2010. PMID: 20713460 Free PMC article.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, Schneider C, Bloehdorn J, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Huber H, et al. Blood. 2022 Mar 3;139(9):1318-1329. doi: 10.1182/blood.2021013208. Blood. 2022. PMID: 35108374 Free article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 39112168
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.
Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M, Goede V, von Tresckow J, Langerbeins P, Fink AM, Huber H, Tausch E, Schneider C, Wendtner CM, Ritgen M, Dreyling M, Müller L, Jacobasch L, Heinz WJ, Vehling-Kaiser U, Sivcheva L, Böttcher S, Dreger P, Illmer T, Gregor M, Staber PB, Stilgenbauer S, Niemann CU, Kater AP, Fischer K, Eichhorst B, Hallek M, Al-Sawaf O. Simon F, et al. Among authors: huber h. J Clin Oncol. 2024 Aug 23:JCO2401192. doi: 10.1200/JCO.24.01192. Online ahead of print. J Clin Oncol. 2024. PMID: 39213466
Biomarkers.
Niotis K, Sisser P, Helfman S, Janney C, Hristov H, Seifan A, Melendez J, Parthasarathy P, McCullough M, Mosse M, Saville D, Colvee H, Saperia C, Angerbauer D, Lakis JP, Huber H, Molfetta GD, Ashton NJ, Zetterberg H, Isaacson RS. Niotis K, et al. Among authors: huber h. Alzheimers Dement. 2024 Dec;20 Suppl 2(Suppl 2):e088292. doi: 10.1002/alz.088292. Alzheimers Dement. 2024. PMID: 39785639 Free PMC article.
Biomarkers.
Huber H, Montoliu-Gaya L, Kern S, Dittrich A, Borroni B, Altomare D, Sander M, Corbett A, Aguilera N, Núñez-Llaves R, García-Gutiérrez F, Jeromin A, Isaacson RS, Palmqvist S, Hansson O, Stomrud E, Boada M, Arús XM, Zetterberg H, Blennow K, Ashton NJ. Huber H, et al. Alzheimers Dement. 2024 Dec;20 Suppl 2(Suppl 2):e092341. doi: 10.1002/alz.092341. Alzheimers Dement. 2024. PMID: 39785496 Free PMC article.
1,122 results